ENRIQUE MARÍA OCIO SAN MIGUEL-rekin lankidetzan egindako argitalpenak (5)

2014

  1. Preclinical activity of the oral proteasome inhibitor mln9708 in myeloma bone disease

    Clinical Cancer Research, Vol. 20, Núm. 6, pp. 1542-1554

  2. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2013

  1. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

    Haematologica, Vol. 98, Núm. 1, pp. 79-86

  2. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

    Leukemia, Vol. 27, Núm. 2, pp. 430-440

2012

  1. Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects

    PLoS ONE, Vol. 7, Núm. 4